PMI-03(PMI-03) - 在研适应症：阿尔茨海默症，神经炎症，帕金森病_专利_临床

概要

基本信息

药物类型

造影剂、小分子化药

别名

靶点-

作用机制

磁共振成像增强剂

治疗领域

神经系统疾病内分泌与代谢疾病其他疾病

在研适应症

阿尔茨海默症神经炎症帕金森病+ [1]

非在研适应症

炎症

原研机构

Precision Molecular Inc.

在研机构

D&D Pharmatech Co., Ltd.初创企业

Precision Molecular Inc.

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 PMI-03 相关的临床结果

登录后查看更多信息

100 项与 PMI-03 相关的转化医学

登录后查看更多信息

100 项与 PMI-03 相关的专利（医药）

登录后查看更多信息

1

项与 PMI-03 相关的文献（医药）

2024-09-01·Legal Medicine

Postmortem changes in the eye on computed tomography images

Article

作者: Yoshimiya, Motoo ; Hyodoh, Hideki ; Shimbashi, Shogo

BACKGROUNDOcular tension decreases with increasing postmortem interval (PMI) and eyes collapse with extreme progression of postmortem change; however, time-related changes in postmortem computed tomography (PMCT) findings have not been clarified. This study aimed to quantitatively evaluate the vitreous volume and CT values of the vitreous body to clarify time-related changes in PMCT.METHODSWe retrospectively reviewed PMCT images of the eyes of subjects who underwent autopsy at our institution between July 2023 and February 2024. They were classified into four PMI groups: PMI-1: < 1 day, PMI-2: 1-2 days, PMI-3: 3-6 days, PMI-4: ≥ 7 days. The vitreous volumes and mean CT values of the vitreous chambers were measured. Additionally, the presence of intraocular gas and crystalline lens dislocation was observed.RESULTSThe PMCT images of 131 eyes of 66 patients (41 males, 25 females) were analyzed. The mean age was 63.7 (22-99) years. The volume of the vitreous cavity was significantly decreased at PMI-3 and PMI-4, which indicated scleral depression. Intraocular gas appeared in PMI-4. Lens dislocation began at PMI-3 and was more frequently observed at PMI-4 and in the higher-temperature environment group.CONCLUSIONOcular findings on PMCT are useful for estimating the time of death.

100 项与 PMI-03 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床1期	韩国	D&D Pharmatech Co., Ltd.初创企业	2022-01-30
神经炎症	临床1期	韩国	D&D Pharmatech Co., Ltd.初创企业	2022-01-30
帕金森病	临床1期	韩国	D&D Pharmatech Co., Ltd.初创企业	2022-01-30
神经变性	临床1期	-	Precision Molecular Inc.	-
神经系统变性病	药物发现	美国	Precision Molecular Inc.	2019-08-22
炎症	药物发现	美国	Precision Molecular Inc.	2019-07-28